Thirty-seven (37) consecutive patients with clinical Stage I (T1-2NO, Mo), and Stage II (T1-2N1 Mo) central small-cell lung cancer (SCLC) underwent complete surgical resection of the primary tumor. Ten patients were subsequently pathologically Stage I, 14 patients were Stage II, and 8 were Stage III (T3;N2). The pathologically Stage I, II, and III patients were then treated with chemotherapy consisting of cyclophosphamide (1 g/m2), doxorubicin (50 mg/m2), and vincristine 2 mg (CAV) every 3 weeks for six courses followed by prophylactic cranial irradiation (2000 cGy in 10 fractions). Median survival in Stage I patients is 162 weeks and calculated 5-year survival is 50%; for Stage II patients, median survival is 86 weeks and calculated 5-year survival is 35%. T3;N2 patients have a median survival of 63 weeks; calculated 5-year survival is 21%. Our data suggest surgery plus adjuvant chemotherapy and cranial irradiation results in long-term survival in early central SCLC. These data support the need for randomized surgical trials in Stage I, II, and III central SCLC.
|Titolo:||A prospective analysis of chemotherapy following surgical resection of clinical stage I-II small-cell lung cancer|
PELICCI, PIER GIUSEPPE (Penultimo)
|Parole Chiave:||Neoplasm Staging; Humans; Vincristine; Aged; Pilot Projects; Cyclophosphamide; Doxorubicin; Carcinoma, Small Cell; Prospective Studies; Lung Neoplasms; Adult; Antineoplastic Combined Chemotherapy Protocols; Middle Aged; Chemotherapy, Adjuvant; Female; Male; Survival Analysis|
|Settore Scientifico Disciplinare:||Settore MED/04 - Patologia Generale|
|Data di pubblicazione:||apr-1993|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1097/00000421-199304000-00001|
|Appare nelle tipologie:||01 - Articolo su periodico|